TY - JOUR
T1 - The Interaction Between Sleep and Metabolism in Alzheimer’s Disease
T2 - Cause or Consequence of Disease?
AU - Carroll, Caitlin M.
AU - Macauley, Shannon L.
N1 - Publisher Copyright:
© Copyright © 2019 Carroll and Macauley.
PY - 2019/9/20
Y1 - 2019/9/20
N2 - Alzheimer’s disease (AD) is the most common form of dementia and affects over 45 million people worldwide. Both type-2-diabetes (T2D), a metabolic condition associated with aging, and disrupted sleep are implicated in the pathogenesis of AD, but how sleep and metabolism interact to affect AD progression remains unclear. In the healthy brain, sleep/wake cycles are a well-coordinated interaction between metabolic and neuronal activity, but when disrupted, are associated with a myriad of health-related issues, including metabolic syndrome, cardiovascular disease, T2D, and AD. Therefore, this review will explore our current understanding of the relationship between metabolism, sleep, and AD-related pathology to identify the causes and consequences of disease progression in AD. Moreover, sleep disturbances and metabolic dysfunction could serve as potential therapeutic targets to mitigate the increased risk of AD in individuals with T2D or offer a novel approach for treating AD.
AB - Alzheimer’s disease (AD) is the most common form of dementia and affects over 45 million people worldwide. Both type-2-diabetes (T2D), a metabolic condition associated with aging, and disrupted sleep are implicated in the pathogenesis of AD, but how sleep and metabolism interact to affect AD progression remains unclear. In the healthy brain, sleep/wake cycles are a well-coordinated interaction between metabolic and neuronal activity, but when disrupted, are associated with a myriad of health-related issues, including metabolic syndrome, cardiovascular disease, T2D, and AD. Therefore, this review will explore our current understanding of the relationship between metabolism, sleep, and AD-related pathology to identify the causes and consequences of disease progression in AD. Moreover, sleep disturbances and metabolic dysfunction could serve as potential therapeutic targets to mitigate the increased risk of AD in individuals with T2D or offer a novel approach for treating AD.
KW - Alzheimer’s disease
KW - glucose
KW - insulin
KW - metabolism
KW - sleep
KW - type-2-diabetes
UR - http://www.scopus.com/inward/record.url?scp=85072972346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072972346&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2019.00258
DO - 10.3389/fnagi.2019.00258
M3 - Review article
AN - SCOPUS:85072972346
SN - 1663-4365
VL - 11
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 258
ER -